Goldman Sachs analyst Matthew Sykes downgrades Singular Genomics Sys (NASDAQ:OMIC) from Buy to Neutral and announces $3.5 price target.
Goldman Sachs Downgrades Singular Genomics Sys to Neutral, Announces $3.5 Price Target
Goldman Sachs analyst Matthew Sykes downgrades Singular Genomics Sys (NASDAQ:OMIC) from Buy to Neutral and announces $3.5 price target.
Related Posts
The Latest Analyst Ratings for SEI Inv
Within the last quarter, SEI Inv (NASDAQ:SEIC) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Innovative Cannabis-Derived Epilepsy Treatment Reaches UK Patients
A leading European pharmaceutical firm specializing in plant-derived medications, MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF) has successfully imported and delivered its ground-breaking Investigational Medicinal Product (IMP), CannEpil, to its first patients in the United Kingdom.
Atlantic Equities Downgrades Vulcan Materials to Neutral, Raises Price Target to $185
Atlantic Equities analyst Colin Isaac downgrades Vulcan Materials (NYSE:VMC) from Overweight to Neutral and raises the price target from $180 to $185.